A new study found that low or absent disease activity, hydroxychloroquine (HCQ) use, and gradual reduction of GC dosing can ...

Exagen Inc. has announced conditional approval from the New York State Department of Health for its innovative new biomarker ...

A new study investigates the role of Krüppel-like factor 2 (KLF2, a protein coding gene involved in a variety of regulatory ...

Lupus affects different people in different ways, and skin problems like rashes or sores re common. In a new study, people ...

The Phase 1 GALLOP study evaluating the investigational therapy, CB-010, for treatment of lupus nephritis has launched.

The Lupus Foundation of America uses an electronic grant submission process. All applicants must submit their full application packages through the ProposalCentral online grants management system.

IGM Biosciences announced the discontinuation of imvotamab and IGM-2644 for autoimmune and inflammatory diseases, including lupus.

There are many ways you can spread awareness of lupus and help bring greater attention and resources to the fight to end lupus. Rallying public support for lupus Through awareness campaigns, celebrity ...

In the Phase 2b CARE study, the investigational drug, cenerimod, demonstrated safe and effective results for treatment of ...

Living with lupus can significantly affect your mental health. This January we are honoring Mental Wellness Month by exploring the intersection of lupus and mental health with a four-part series of ...